SCHEMBL5668151

SCHEMBL5668151

CC(C)(C)OC(=O)N1Cc2cc(NC(=O)c3ccccc3NCc3c[nH]c4c(F)cccc34)ccc2C(C)(C)C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 6/20 0.37
MAPT P10636 2/20 0.34
BACE1 P56817 1/20 0.34
CNR1 P21554 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
GPR35 Q9HC97 1/20 0.34
GPR55 Q9Y2T6 1/20 0.34
SCN4A P35499 1/20 0.34
SCN3A Q9NY46 1/20 0.34
NPC1 O15118 1/20 0.33
TP53 P04637 1/20 0.33
NFKB1 P19838 1/20 0.33
HTT P42858 1/20 0.33
RAB9A P51151 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TMPRSS2 O15393 1/20 0.33
NR1H2 P55055 1/20 0.33
NAMPT P43490 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5628140 0.87 KIT (0.37) RXFP1SCN4ASCN3ANR1H2NAMPT
SCHEMBL5627073 0.83 RXFP1 (0.41) RXFP1TP53NR1H2NAMPTABL1
SCHEMBL5625932 0.81 RXFP1 (0.40) RXFP1MAPTNR1H2NAMPTPTGES
SCHEMBL4971088 0.80 KDR (0.45) NR1H2WEE1ABL1EGFRCSF1R
SCHEMBL14348672 0.79 KIT (0.40) RXFP1NR1H2NAMPTABL1EGFR
SCHEMBL5626921 0.77 KIT (0.44) KIT
SCHEMBL5626252 0.76 KIT (0.54) RXFP1NR1H2NAMPTWEE1KIT
SCHEMBL5626772 0.76 NR1H2 (0.41) NPC1RAB9ATMPRSS2NR1H2NAMPT
SCHEMBL445073 0.74 NR1H2 (0.41) RXFP1MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL3156350 0.73 KDR (0.44) NR1H2WEE1ABL1EGFRCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7307088-B2 Substituted anthranilic amide derivatives and methods of use AMGEN INC. (US) 2007-12-11 US disclosed
US-7307088-B2 Substituted anthranilic amide derivatives and methods of use AMGEN INC. (US) 2007-12-11 US disclosed
US-7307088-B2 Substituted anthranilic amide derivatives and methods of use AMGEN INC. (US) 2007-12-11 US disclosed
US-20040087568-A1 Substituted anthranilic amide derivatives and methods of use AMGEN INC. 2004-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087568-A1 Substituted anthranilic amide derivatives and methods of use AADAC, ASPH, EGLN3 RXFP1 1275/4885MAPT 4542/4885BACE1 3236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.